Cervical cancer remains one of the leading causes of cancer-related mortality among women worldwide, particularly in developing countries. While early screening and HPV vaccination have significantly reduced incidence rates, advanced and recurrent stages of cervical cancer still pose major treatment challenges. Conventional therapies such as chemotherapy and radiotherapy often result in systemic toxicity and limited efficacy. In this context, monoclonal antibodies (mAbs) have emerged as a powerful and targeted therapeutic option, capable of offering greater precision with fewer side effects.
Monoclonal antibodies are engineered proteins that bind specifically to antigens expressed on tumor cells or within the tumor microenvironment. In cervical cancer, several key targets have been identified, including vascular endothelial growth factor (VEGF) and programmed death-ligand 1 (PD-L1). The anti-VEGF mAb bevacizumab was the first to be approved for advanced cervical cancer and has shown to significantly improve progression-free and overall survival when combined with chemotherapy by inhibiting tumor angiogenesis.
Checkpoint inhibitors such as pembrolizumab and nivolumab, which target the PD-1/PD-L1 axis, have demonstrated promising results in restoring T-cell activity and enhancing immune-mediated tumor cell killing in patients with recurrent or metastatic disease. These immune-based therapies mark a paradigm shift toward precision oncology in cervical cancer treatment.
Furthermore, antibody–drug conjugates (ADCs) represent an evolving strategy, combining monoclonal antibodies with potent cytotoxic drugs to deliver targeted therapy directly to cancer cells. Emerging targets such as tissue factor (TF) and epidermal growth factor receptor (EGFR) are currently under clinical investigation to further expand the treatment arsenal.
This paper explores the structural and functional aspects of monoclonal antibodies in the context of cervical cancer, detailing their mechanisms, clinical relevance, and future prospects. With continued research and development, monoclonal antibodies are poised to redefine the therapeutic landscape of cervical cancer by offering safer, more effective, and personalized treatment options.
